News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

ISCORE, a RECOVER hub spanning 10 states and Puerto Rico, is bringing Long COVID studies to communities often underfunded in research, drawing on decades of HIV experience to tackle another new infectious disease.
RECOVER scientists, study participants, and Representatives are working together to make new discoveries about Long COVID and how to diagnose, prevent, and treat its symptoms.
As RECOVER’s adult observational study moves to the next phase, researchers continue to explore the various causes of common Long COVID symptoms, such as difficulty breathing.
At the RECOVER Research Review (R3) Seminar held on April 14, RECOVER researchers presented findings on how Long COVID affects the brain, including difficulties with thinking clearly, memory, and concentration. They also outlined future research opportunities to better understand neurocognitive symptoms and how other body systems impact brain health.
Patients, caregivers, and researchers will have 2 weeks to provide input on plans to test whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can help improve Long COVID symptoms.
RECOVER researchers are continuing plans to explore cognitive symptoms like brain fog in the initiative’s adult observational study, one of the most common but least understood symptoms of Long COVID.
The RECOVER-AUTONOMIC (Ivabradine) clinical trial tested whether ivabradine, an oral medication used to lower heart rate, could be used to manage a Long COVID symptom called postural orthostatic tachycardia syndrome (POTS).
RECOVER recognizes International Long COVID Awareness Day on March 15—a day established by the Long COVID community to increase visibility of the condition, share resources, and educate the public.